Abilify Wins FDA Approval
Bristol-Myers Squibb Company and Otsuka Pharmaceutical Company won FDA approval for Abilify (aripiprazole) for the treatment of acute bipolar mania, including manic and mixed episodes associated with bipolar disorder.
Phase-II data show reduced hepatitis-C RNA levels among HIV-positive patients, the drugmaker shared at a medical meeting. Boehringer also released co-infection data.
The newly titled Nurse Practitioner Perspective rolls out this month, keeping pace with an educational shift in the nursing field.
The issue: Boehringer's manufacturing site. The FDA is not asking for new clinical studies.